RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33750796.
- Also identified by DOI 10.1038/s41467-021-21828-7 and PMC identifier 7943813.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Growing evidences suggest that cancer stem cells exhibit many molecular characteristics and phenotypes similar to their ancestral progenitor cells. In the present study, human embryonic stem cells are induced to differentiate into hepatocytes along hepatic lineages to mimic liver development in vitro. A liver progenitor specific gene, RALY RNA binding protein like (RALYL), is identified. RALYL expression is associated with poor prognosis, poor differentiation, and metastasis in clinical HCC patients. Functional studies reveal that RALYL could promote HCC tumorigenicity, self-renewal, chemoresistance, and metastasis. Moreover, molecular mechanism studies show that RALYL could upregulate TGF-β2 mRNA stability by decreasing N6-methyladenosine (m<sup>6</sup>A) modification. TGF-β signaling and the subsequent PI3K/AKT and STAT3 pathways, upregulated by RALYL, contribute to the enhancement of HCC stemness. Collectively, RALYL is a liver progenitor specific gene and regulates HCC stemness by sustaining TGF-β2 mRNA stability. These findings may inspire precise therapeutic strategies for HCC.
Medical subject headings
- Carcinoma, Hepatocellular
- Heterogeneous-Nuclear Ribonucleoprotein Group C
- Liver Neoplasms
- RNA Stability
- Transforming Growth Factor beta2